Education
About Us
Working with TipRanks
Follow Us
Universe Pharmaceuticals (UPC)
NASDAQ:UPC
UPC Stock Chart & Stats
$4.22
-$0.02(-3.13%)
At close: 4:00 PM EST
$4.22
-$0.02(-3.13%)
Day’s Range― - ―
52-Week Range$2.00 - $11.00
Previous CloseN/A
Volume250.22K
Average Volume (3M)955.25K
Market Cap
$1.35M
Enterprise Value-$22.98M
Total Cash (Recent Filing)$33.59M
Total Debt (Recent Filing)$9.26M
Price to Earnings (P/E)―
Beta1.57
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding563,338
10 Day Avg. Volume2,486,504
30 Day Avg. Volume955,249
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00082
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-17.00
Enterprise Value/Revenue-1.29
Enterprise Value/Gross Profit-3.65
Enterprise Value/Ebitda7.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Manageable DebtModest absolute debt and a low debt-to-equity ratio provide durable financial flexibility. With conservative leverage the company faces lower refinancing and interest-risk, enabling it to fund operations or bridge near-term cash needs without immediate distress while pursuing a revenue recovery.
Improving Margins In 2025A meaningful gross-margin rebound and narrower net loss show structural progress on pricing, mix, or cost control. If sustained, higher margins reduce cash burn per unit of revenue and materially improve the path to break-even even if revenue recovery is gradual.
Distribution Footprint & Aging-demographic FocusA broad provincial distribution network and explicit focus on elderly-health products align with a secular demographic tailwind in China. Diversified geographic reach and distributor capabilities can sustain product access and provide a base for stable recurring revenue if product-market fit holds.
Bears Say
Multi-year Revenue Decline And Sustained LossesA prolonged decline in revenue and consecutive annual losses point to persistent demand or execution problems. Losses over multiple years erode operating scale and can negate margin gains, making a durable recovery dependent on materially reversing the top-line trend.
Negative Operating And Free Cash FlowConsistent negative operating and free cash flow forces reliance on external funding or equity, constraining investment and commercialization capacity. Even with improving outflows, ongoing cash burn is a structural risk to sustainability absent durable profit or new financing sources.
Dual-class Share Structure / Governance ConcentrationImplementing a dual-class structure materially concentrates control with insiders. That durable governance change can entrench management, reduce minority shareholder influence and oversight, and raise long-term execution and strategic-risk if interests diverge from public investors.
Universe Pharmaceuticals News
UPC FAQ
What was Universe Pharmaceuticals’s price range in the past 12 months?
Universe Pharmaceuticals lowest stock price was $2.00 and its highest was $11.00 in the past 12 months.
What is Universe Pharmaceuticals’s market cap?
Universe Pharmaceuticals’s market cap is $1.35M.
When is Universe Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universe Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Universe Pharmaceuticals overvalued?
According to Wall Street analysts Universe Pharmaceuticals’s price is currently Overvalued.
Does Universe Pharmaceuticals pay dividends?
Universe Pharmaceuticals does not currently pay dividends.
What is Universe Pharmaceuticals’s EPS estimate?
Universe Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universe Pharmaceuticals have?
Universe Pharmaceuticals has 563,338 shares outstanding.
What happened to Universe Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Universe Pharmaceuticals?
Currently, no hedge funds are holding shares in UPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universe Pharmaceuticals
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.
Technical Analysis
China Pharma Holdings
―
RedHill Biopharma
―
China SXT Pharmaceuticals
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―